Indication

Non-muscle invasive bladder cancer with carcinoma in situ

Non-muscle invasive bladder cancer with carcinoma in situ refers to high-grade urothelial malignancy confined to the inner mucosal lining of the urinary bladder without invasion into the underlying detrusor muscle layer. Read more about Non-muscle invasive bladder cancer with carcinoma in situ

7 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Non-muscle invasive bladder cancer with carcinoma in situ therapies.

Showing 1–7 of 7 drugs

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme
Filter & compare in the drug finder →Opens the drug finder with Non-muscle invasive bladder cancer with carcinoma in situ preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Non-muscle invasive bladder cancer with carcinoma in situ.

Non-muscle invasive bladder cancer with carcinoma in situ refers to high-grade urothelial malignancy confined to the inner mucosal lining of the urinary bladder without invasion into the underlying detrusor muscle layer.

Unlike exophytic papillary lesions, carcinoma in situ appears pathologically as a flat, poorly differentiated lesion that carries a substantially elevated risk of disease recurrence and progression to muscle-invasive or metastatic disease.

It primarily affects older adults, presenting either alone (primary Tis) or concurrently with papillary tumors, and commonly manifests with microscopic or gross hematuria and irritative lower urinary tract symptoms.

Personalize your experience

Follow Non-muscle invasive bladder cancer with carcinoma in situ and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it